March 2012
Volume 53, Issue 14
ARVO Annual Meeting Abstract  |   March 2012
The Role of Nitric Oxide in Dry and Wet Age-related Macular Degeneration
Author Affiliations & Notes
  • Sarah B. Sunshine
    Johns Hopkins School of Medicine, Baltimore, Maryland
  • Joel C. Sunshine
    Biomedical Engineering,
    Johns Hopkins School of Medicine, Baltimore, Maryland
  • Marisol Cano
    Johns Hopkins School of Medicine, Baltimore, Maryland
  • James T. Handa
    Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland
  • Footnotes
    Commercial Relationships  Sarah B. Sunshine, None; Joel C. Sunshine, None; Marisol Cano, None; James T. Handa, None
  • Footnotes
    Support  Thome Foundation Grant (JTH), NIH Grant EY019904 (JTH), Unrestricted grant from RPB (JTH), HHMI-FFB Medical Research Fellow (SBS)
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 3189. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sarah B. Sunshine, Joel C. Sunshine, Marisol Cano, James T. Handa; The Role of Nitric Oxide in Dry and Wet Age-related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2012;53(14):3189.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Age-related Macular Degeneration (AMD), the most common cause of blindness among the elderly in the US, has two forms. The "dry" form, characterized by retinal pigment epithelial (RPE) cell apoptosis and the "wet" form, characterized by pathologic angiogenesis. Nitric Oxide (NO) is a chief component of cigarette smoke (CS), the strongest risk factor for AMD. NO activates the cytoprotective transcription factor Nrf2. CS and NO induce RPE apoptosis, vascular permeability, and angiogenesis unless neutralized. NO from CS or neuronal nitric oxide synthase (nNOS), the predominant isoform in the RPE, could injure the RPE by impairing the Nrf2 response. We hypothesize that acute NO exposure induces the Nrf2 response whereas chronic NO causes Nrf2 failure, leading to dry AMD, and through NO’s pro-angiogenic properties, activate wet AMD.

Methods: : NO was measured (DAF2DA) in ARPE19 cells treated with CS, SNAP (NO donor), or transfected with nNOS. The Nrf2 response was tested by measuring Nrf2 responsive gene (GCLM, NQO1, HO1) expression by RT-qPCR. Control and nNOS deficient mice were treated with NOS’s substrate, Arginine (70mg/ml), to increase NO, or water for 1-6 months. Laser induced rupture of Bruch’s membrane was used to generate choroidal neovascularization (CNV).

Results: : CS and nNOS transfected ARPE19 cells showed increased NO (10 and 2 fold) and increased expression of Nrf2 (1.6-fold p=0.05), GCLM (1.39-fold p=0.02), NQO1 (2.7-fold, p=0.005). Mice treated with arginine had increased expression of GCLM (2.13-fold, p=0.01), NQO1-(1.85-fold, p=0.04), HO1 (2.25-fold, p=0.03) at 6 months in the RPE, and no Nrf2 response in nNOS deficient mice. The area of CNV was paradoxically decreased by 41% (p=0.004) in arginine treated mice compared to controls.

Conclusions: : Nrf2 protects the RPE from acute NO stress. NO from nNOS production likely mediated the Nrf2 response in the RPE of mice chronically exposed to arginine. A dramatic decrease in CNV size was observed in mice treated with arginine possibly through activated arginase. Further investigation of arginase is warranted as a potential new therapy for wet AMD.

Keywords: age-related macular degeneration • nitric oxide • oxidation/oxidative or free radical damage 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.